{"title":"与抗精神病药相关的乳腺癌","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31212","DOIUrl":null,"url":null,"abstract":"<p>Research data suggest an association between antipsychotic-induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti-dopaminergic properties of antipsychotics, especially those of first-generation agents.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 10","pages":"2"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antipsychotic-associated breast cancer\",\"authors\":\"Y. W. Francis Lam Pharm.D., FCCP\",\"doi\":\"10.1002/pu.31212\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Research data suggest an association between antipsychotic-induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti-dopaminergic properties of antipsychotics, especially those of first-generation agents.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"35 10\",\"pages\":\"2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31212\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31212","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Research data suggest an association between antipsychotic-induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti-dopaminergic properties of antipsychotics, especially those of first-generation agents.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
